| First Author | Bochenek ML | Year | 2020 |
| Journal | Circ Res | Volume | 126 |
| Issue | 2 | Pages | 162-181 |
| PubMed ID | 31747868 | Mgi Jnum | J:307026 |
| Mgi Id | MGI:6710247 | Doi | 10.1161/CIRCRESAHA.119.315259 |
| Citation | Bochenek ML, et al. (2020) Activated Endothelial TGFbeta1 Signaling Promotes Venous Thrombus Nonresolution in Mice Via Endothelin-1: Potential Role for Chronic Thromboembolic Pulmonary Hypertension. Circ Res 126(2):162-181 |
| abstractText | RATIONALE: Chronic thromboembolic pulmonary hypertension (CTEPH) is characterized by defective thrombus resolution, pulmonary artery obstruction, and vasculopathy. TGFbeta (transforming growth factor-beta) signaling mutations have been implicated in pulmonary arterial hypertension, whereas the role of TGFbeta in the pathophysiology of CTEPH is unknown. OBJECTIVE: To determine whether defective TGFbeta signaling in endothelial cells contributes to thrombus nonresolution and fibrosis. METHODS AND RESULTS: Venous thrombosis was induced by inferior vena cava ligation in mice with genetic deletion of TGFbeta1 in platelets (Plt.TGFbeta-KO) or TGFbeta type II receptors in endothelial cells (End.TGFbetaRII-KO). Pulmonary endarterectomy specimens from CTEPH patients were analyzed using immunohistochemistry. Primary human and mouse endothelial cells were studied using confocal microscopy, quantitative polymerase chain reaction, and Western blot. Absence of TGFbeta1 in platelets did not alter platelet number or function but was associated with faster venous thrombus resolution, whereas endothelial TGFbetaRII deletion resulted in larger, more fibrotic and higher vascularized venous thrombi. Increased circulating active TGFbeta1 levels, endothelial TGFbetaRI/ALK1 (activin receptor-like kinase), and TGFbetaRI/ALK5 expression were detected in End.TGFbetaRII-KO mice, and activated TGFbeta signaling was present in vessel-rich areas of CTEPH specimens. CTEPH-endothelial cells and murine endothelial cells lacking TGFbetaRII simultaneously expressed endothelial and mesenchymal markers and transcription factors regulating endothelial-to-mesenchymal transition, similar to TGFbeta1-stimulated endothelial cells. Mechanistically, increased endothelin-1 levels were detected in TGFbetaRII-KO endothelial cells, murine venous thrombi, or endarterectomy specimens and plasma of CTEPH patients, and endothelin-1 overexpression was prevented by inhibition of ALK5, and to a lesser extent of ALK1. ALK5 inhibition and endothelin receptor antagonization inhibited mesenchymal lineage conversion in TGFbeta1-exposed human and murine endothelial cells and improved venous thrombus resolution and pulmonary vaso-occlusions in End.TGFbetaRII-KO mice. CONCLUSIONS: Endothelial TGFbeta1 signaling via type I receptors and endothelin-1 contribute to mesenchymal lineage transition and thrombofibrosis, which were prevented by blocking endothelin receptors. Our findings may have relevant implications for the prevention and management of CTEPH. |
